CN114555589B - 用于抑制ezh2的化合物和组合物 - Google Patents

用于抑制ezh2的化合物和组合物 Download PDF

Info

Publication number
CN114555589B
CN114555589B CN202180005903.7A CN202180005903A CN114555589B CN 114555589 B CN114555589 B CN 114555589B CN 202180005903 A CN202180005903 A CN 202180005903A CN 114555589 B CN114555589 B CN 114555589B
Authority
CN
China
Prior art keywords
amino
methyl
chloro
methylquinolin
cyclohexyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180005903.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN114555589A (zh
Inventor
代璇
迈克·多尔
顾祥巨
李玲
刘康志
麦星洋
米沅
欧阳孔德
朱利恩·帕皮伦
费琦
严小霞
郁征天
张继跃
赵克浩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Priority to CN202411371645.6A priority Critical patent/CN119431341A/zh
Publication of CN114555589A publication Critical patent/CN114555589A/zh
Application granted granted Critical
Publication of CN114555589B publication Critical patent/CN114555589B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202180005903.7A 2020-08-10 2021-08-10 用于抑制ezh2的化合物和组合物 Active CN114555589B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411371645.6A CN119431341A (zh) 2020-08-10 2021-08-10 用于抑制ezh2的化合物和组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/108213 2020-08-10
CN2020108213 2020-08-10
PCT/CN2021/111910 WO2022033492A1 (en) 2020-08-10 2021-08-10 Quinoline compounds and compositions for inhibiting ezh2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411371645.6A Division CN119431341A (zh) 2020-08-10 2021-08-10 用于抑制ezh2的化合物和组合物

Publications (2)

Publication Number Publication Date
CN114555589A CN114555589A (zh) 2022-05-27
CN114555589B true CN114555589B (zh) 2024-10-25

Family

ID=77520462

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180005903.7A Active CN114555589B (zh) 2020-08-10 2021-08-10 用于抑制ezh2的化合物和组合物
CN202411371645.6A Pending CN119431341A (zh) 2020-08-10 2021-08-10 用于抑制ezh2的化合物和组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411371645.6A Pending CN119431341A (zh) 2020-08-10 2021-08-10 用于抑制ezh2的化合物和组合物

Country Status (12)

Country Link
US (1) US12473273B2 (cg-RX-API-DMAC10.html)
EP (1) EP4041725B1 (cg-RX-API-DMAC10.html)
JP (1) JP7768880B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230051116A (cg-RX-API-DMAC10.html)
CN (2) CN114555589B (cg-RX-API-DMAC10.html)
AR (1) AR123185A1 (cg-RX-API-DMAC10.html)
AU (1) AU2021323828B2 (cg-RX-API-DMAC10.html)
CA (1) CA3180139A1 (cg-RX-API-DMAC10.html)
ES (1) ES2985111T3 (cg-RX-API-DMAC10.html)
IL (1) IL297332B2 (cg-RX-API-DMAC10.html)
TW (1) TWI910207B (cg-RX-API-DMAC10.html)
WO (1) WO2022033492A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR123185A1 (es) 2020-08-10 2022-11-09 Novartis Ag Compuestos y composiciones para inhibir ezh2
PE20241731A1 (es) * 2022-02-01 2024-08-19 Lilly Co Eli Procesos para la preparacion de degradadores selectivos del receptor de estrogeno
CN117384153A (zh) * 2022-07-12 2024-01-12 上海赛岚生物科技有限公司 一类甲基转移酶抑制剂及其用途
CN118515653B (zh) * 2024-07-23 2024-12-10 西湖制药(杭州)有限公司 一种ezh2特异性抑制剂及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021057853A1 (en) * 2019-09-26 2021-04-01 Novartis Ag Aza-quinoline compounds and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
JP2002532415A (ja) 1998-12-16 2002-10-02 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤による関節炎の治療
AU7349801A (en) 2000-07-19 2002-01-30 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
CA2478065C (en) 2002-03-08 2013-01-08 Eisai Co. Ltd. Macrocyclic compounds useful as pharmaceuticals
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
SE0202134D0 (sv) * 2002-07-08 2002-07-08 Astrazeneca Ab Therapeutic agents
JP2006124387A (ja) 2004-09-30 2006-05-18 Taisho Pharmaceut Co Ltd 新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
MX2008002114A (es) 2005-07-21 2008-04-17 Ardea Biosciences Inc Inhibidores de n-(arilamino)-sulfonamida de mek.
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
BRPI0816769A2 (pt) 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
WO2009055730A1 (en) 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
WO2012068589A2 (en) * 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
AP2016009605A0 (en) * 2014-06-17 2016-12-31 Pfizer Substituted dihydroisoquinolinone compounds
JP2019524872A (ja) * 2016-06-20 2019-09-05 ノバルティス アーゲー 癌の治療に有用なイミダゾピリミジン化合物
WO2018195450A1 (en) 2017-04-21 2018-10-25 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
CN109912576B (zh) * 2019-03-20 2021-11-19 华东理工大学 环状或螺环二胺类嘧啶-异羟肟酸及其用途
AR123185A1 (es) 2020-08-10 2022-11-09 Novartis Ag Compuestos y composiciones para inhibir ezh2

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021057853A1 (en) * 2019-09-26 2021-04-01 Novartis Ag Aza-quinoline compounds and uses thereof

Also Published As

Publication number Publication date
AR123185A1 (es) 2022-11-09
TWI910207B (zh) 2026-01-01
CA3180139A1 (en) 2022-02-17
US20230167100A1 (en) 2023-06-01
JP7768880B2 (ja) 2025-11-12
EP4041725A1 (en) 2022-08-17
WO2022033492A1 (en) 2022-02-17
KR20230051116A (ko) 2023-04-17
US12473273B2 (en) 2025-11-18
JP2023538159A (ja) 2023-09-07
AU2021323828A1 (en) 2022-05-19
CN119431341A (zh) 2025-02-14
IL297332B1 (en) 2025-10-01
ES2985111T3 (es) 2024-11-04
IL297332A (en) 2022-12-01
EP4041725B1 (en) 2024-03-27
CN114555589A (zh) 2022-05-27
IL297332B2 (en) 2026-02-01
TW202220979A (zh) 2022-06-01
AU2021323828B2 (en) 2026-07-30

Similar Documents

Publication Publication Date Title
CN107108637B (zh) 三唑并嘧啶化合物及其用途
CN109906224B (zh) 三唑吡啶化合物及其应用
JP7768880B2 (ja) Ｅｚｈ２を阻害するためのキノリン化合物および組成物
CN114746414B (zh) 氮杂-喹啉化合物及其用途
EP3472166A1 (en) Imidazopyrimidine compounds useful for the treatment of cancer
CA3145864A1 (en) Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
HK40117897A (en) Compounds and compositions for inhibiting ezh2
HK40080941B (en) Quinoline compounds and compositions for inhibiting ezh2 as a treatment for cancer diseases
HK40080941A (en) Quinoline compounds and compositions for inhibiting ezh2 as a treatment for cancer diseases
HK40077297B (en) Aza-quinoline compounds and uses thereof
HK40077297A (en) Aza-quinoline compounds and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant